Xuewen Wu

Dr. Xuewen Wu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2017 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
SXShaobing Xie
Shaobing Xie
QQQingfen Qiang
Qingfen Qiang
LMLingyun Mei
Lingyun Mei
CHChufeng He
Chufeng He
YFYong Feng
Yong Feng
XWXuewen Wu
Xuewen Wu

29 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
XWXuewen Wu
Xuewen Wu
LZLi Zhang
Li Zhang
YLYihui Li
Yihui Li
WZWenjuan Zhang
Wenjuan Zhang
JWJianjun Wang
Jianjun Wang
XLXi Lin
Xi Lin
Mutations in voltage-gated potassium channel KCNE1 cause Jervell and Lange-Nielsen syndrome type 2 (JLNS2), resulting in congenital deafness and vestibular dysfunction. We conducted gene therapy by injecting viral vectors using the canalostomy approach in Kcne1−/− mice to treat both the hearing and vestibular symptoms. Results showed early treatment prevented collapse of the Reissner’s membrane and vestibular wall, retained the normal size of the semicircular canals, and prevented the degeneration of inner ear cells. In a dose-dependent manner, the treatment preserved auditory (16 out of 20 mice) and vestibular (20/20) functions in mice treated with the high-dosage for at least five months. In the low-dosage group, a subgroup of mice (13/20) showed improvements only in the vestibular functions. Results supported that highly efficient transduction is one of the key factors for achieving the efficacy and maintaining the long-term therapeutic effect. Secondary outcomes of treatment included improved birth and litter survival rates. Our results demonstrated that gene therapy via the canalostomy approach, which has been considered to be one of the more feasible delivery methods for human inner ear gene therapy, preserved auditory and vestibular functions in a dose-dependent manner in a mouse model of JLNS2.

1 September 2019 in Otology & Neurotology
Verified
Journal Article
Closed access
YZYanni Zhang
Yanni Zhang
QJQian Jiang
Qian Jiang
XWXuewen Wu
Xuewen Wu
SXShaobing Xie
Shaobing Xie
YFYong Feng
Yong Feng
HSHong Sun
Hong Sun
Objectives: We aimed to verify the hypothesis that metabolic syndrome (MetS) and its components affect the prognosis of idiopathic sudden sensorineural hearing loss (ISNNHL). Study Design: A retrospective cohort study. Setting: Tertiary otology referral center. Patients: We divided patients who were diagnosed with ISSNHL between January 2015 and January 2018 into a MetS group and a Non-MetS group according to the diagnostic criteria of MetS. Interventions: We diagnosed ISSNHL patients by using pure-tone audiometry and treated them with oral steroids, blood flow promoting agents, and hyperbaric oxygen therapy. Main Outcome Measures: We used multivariate logistic analysis to identify prognostic factors of ISSNHL. Results: The MetS group comprised 94 patients, and the Non-MetS group comprised 162 subjects. Despite the rate of hypertension, diabetes mellitus, hyperlipidemia, and BMI, no significant difference was observed between the two groups (p > 0.05). The rates of complete recovery and partial recovery of the MetS group were significantly lower than those of the Non-MetS group (p < 0.05). According to the multivariate analysis, MetS was significantly correlated with a poor prognosis (OR = 2.912, p = 0.008), and the OR increased with an increase in the number of MetS components. Late onset of treatment, high initial hearing threshold, and presence of diabetes mellitus and hyperlipidemia were associated with a poor prognosis (p < 0.05). Conclusions: The presence of MetS may negatively affect the recovery of Chinese patients with ISSNHL, and the prognosis was poorer with an increase in the number of MetS components. Early onset of treatment, low initial hearing threshold and absence of diabetes mellitus, and hyperlipidemia are associated with favorable hearing recovery.

4 December 2019 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
SXShaobing Xie
Shaobing Xie
HNHongting Ning
Hongting Ning
YSYongchuan She
Yongchuan She
QJQiancheng Jing
Qiancheng Jing
QJQian Jiang
Qian Jiang
XWXuewen Wu
Xuewen Wu

27 November 2019 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
XWXuewen Wu
Xuewen Wu
WZWenjuan Zhang
Wenjuan Zhang
YLYihui Li
Yihui Li
XLXi Lin
Xi Lin
Connexins (Cxs) are ubiquitous membrane proteins that are found throughout vertebrate organs, acting as building blocks of the gap junctions (GJs) known to play vital roles in the normal function of many organs. Mutations in Cx genes (particularly GJB2, which encodes Cx26) cause approximately half of all cases of congenital hearing loss in newborns. Great progress has been made in understanding GJ function and the molecular mechanisms for the role of Cxs in the cochlea. Data reveal that multiple types of Cxs work together to ensure normal development and function of the cochlea. These findings include many aspects not proposed in the classic K+ recycling theory, such as the formation of normal cochlear morphology (e.g., the opening of the tunnel of Corti), the fine-tuning of the innervation of nerve fibers to the hair cells (HCs), the maturation of the ribbon synapses, and the initiation of the endocochlear potential (EP). New data, especially those collected from targeted modification of major Cx genes in the mouse cochlea, have demonstrated that Cx26 plays an essential role in the postnatal maturation of the cochlea. Studies also show that Cx26 and Cx30 assume very different roles in the EP generation, given that only Cx26 is required for normal hearing. This article will review our current understanding of the molecular structure, cellular distribution, and major functions of cochlear GJs. Potential implications of the knowledge of cochlear GJs on the design and implementation of translational studies of cochlear gene therapies for Cx mutations are also discussed.

27 August 2019 in Journal of International Medical Research
Verified
Journal Article
Open access
PDF file
SXShaobing Xie
Shaobing Xie
XWXuewen Wu
Xuewen Wu
Sudden sensorineural hearing loss (SSNHL) is a relatively rare, but distressing, disease in pregnant women. Little is known about the causes, clinical manifestations, treatments, and prognosis of SSNHL. Some hypotheses have been proposed to explain the pathophysiological mechanism of SSNHL, but most of them have not been identified. This article reviews the existing literature to present a summary of this clinical problem. Most patients suffer from SSNHL in the second or third trimester, and show moderate to profound hearing loss. The interval between the initial treatment and onset of hearing loss is less than 10 days in most patients. Some patients with SSNHL show tinnitus, vertigo, or dizziness, and fullness of the ear. Although some patients have a tendency for self-cure, treatment with intravenous dextran 40 combined with intratympanic corticosteroids is probably a safe and effective therapeutic strategy for pregnant patients with SSNHL. Further clinical research is necessary to identify the best therapeutic strategy for these patients.